Pages

▼
Friday, May 27, 2016

What the thrombocytopenia findings mean for Ionis Pharmaceuticals

›
Yesterday, Ionis Pharmaceuticals disclosed that severe reductions in platelets had been observed in phase III clinical trials of both ION...
Monday, August 31, 2015

Cholesterol-lowering RNAi Therapeutic Shocks Monoclonal Antibody Establishment

›
Not too long ago, RNAi Therapeutic got dumped by Big Pharma in a big way not least because of the monoclonal/recombinant protein pedigree ...
Tuesday, June 23, 2015

The RNAi Therapeutics Blog is Taking a Break

›
When it feels that everything has been said, it may be time to be silent for a while. This point has come for me and the RNAi Therapeutic...
14 comments:
Thursday, June 11, 2015

There is No Doubt: Splice Modulator Drug for Spinal Muscular Atrophy Works

›
The fairy-tale story of the splice modulation for spinal muscular atrophy (SMA) continues .   This morning, Isis Pharmaceuticals provided ...
11 comments:
Wednesday, June 10, 2015

Alnylam Slams Dicerna with Trade Secret Complaint

›
How times have changed .  Four years ago, Alnylam found itself  on the receiving end of a trade secret lawsuit regarding the delivery tech...
10 comments:
Thursday, June 4, 2015

What to Watch for in RG-101 Post Regulus Therapeutics Executive Departures

›
As you will probably know already, Regulus Therapeutics surprised us this week with the sudden departures of both their CEO and CSO.  Thes...
7 comments:
Thursday, May 28, 2015

RXi Pharmaceuticals Could Be Much More Than Skin Wound Healing

›
RXi Pharmaceuticals today commenced a secondary offering setting it on course to raise ~$10M, enough to finance the company for another ...
9 comments: